Senti Biosciences Holdings, Inc. reported that its wholly owned subsidiary issued and sold $4.0 million in aggregate principal amount of Senior Secured Convertible Notes to Celadon Partners SPV 24 on August 14, 2026, pursuant to a Securities Purchase Agreement dated April 27, 2026. The filing also disclosed that the company filed a preliminary proxy statement on July 21, 2026, regarding potential transactions involving a merger with an entity affiliated with Celadon and the issuance of contingent value rights potentially paying up to $60.0 million in cash based on regulatory and sales milestones for its product candidate SENTI-202. The company operates in the biotechnology industry, focusing on developing synthetic biology-based therapeutics.
